B. Shah

R. Woessner, M. Kaul, A. Drollmann, 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmacokinetics, Pharmacodynamics, and Safety of a Lipid-Lowering Adenosine A1 Agonist, RPR749, in Healthy Subjects

B. Jensen, S. Rohatagi, C. Natarajan, 2004, American journal of therapeutics.

Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator

T. Langenickel, B. Poller, H. Weiss, 2021, Drug Metabolism and Disposition.

Mass Balance Study of [14C]M100240, a Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, in Healthy Male Subjects

B. Jensen, S. Rohatagi, N. Martin, 2003, American journal of therapeutics.

A Study Comparing the Clinical Pharmacokinetics, Pharmacodynamics, and Tolerability of Triamcinolone Acetonide HFA‐134a Metered‐Dose Inhaler and Budesonide Dry‐Powder Inhaler following Inhalation Administration

D. Argenti, D. Heald, B. Shah, 2000, Journal of clinical pharmacology.

Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers

B. Boutouyrie, B. Jensen, P. Zannikos, 1999, Journal of clinical pharmacology.

A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants

R. Woessner, L. Klickstein, W. Prince, 2022, Clinical pharmacology in drug development.

Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment

R. Woessner, W. Prince, R. Stringer, 2021, Journal of clinical pharmacology.